San Francisco, 8 November 2018 – According to a report published by Grand View Research, Inc.; the global research antibodies market is expected to reach around USD 4.30 billion by 2025. Increasing investments in research and development (R&D) activities can propel the market during the forecast period (2014 to 2025).
High prevalence of cancer is the primary driving factor for the global market expansion. Use of research antibodies in initial detection of cancer has also been gaining prominence in the medical sector. Academic and research institutes and pharmaceuticals and biotechnology companies are focusing on development of next generation therapeutics and personalized medicines due to prevalence of cancer and chronic diseases. Development of personalized medicine is the key trend observed in the market.
The worldwide research antibodies market is segmented on the basis of product, type, technology, source, application, end-use, and region. Based on product, the market is classified into primary and secondary. In 2016, primary antibodies was the leading product segment. High adoption in research activities owing to better specificity, easy availability, and suitability to different research requirements are expected to bode well for the demand of antibodies. The segment is likely to hold more than 65.0% of overall market share by 2025. Secondary segment is anticipated to display stable CAGR owing to cost-effectiveness and availability in ready-to-use form as reagents.
As per type, the market for research antibodies is bifurcated into monoclonal and polyclonal antibodies. In 2016, the monoclonal segment held the largest market share due to their efficient staining properties with less background noise and high sensitivity for detection of antigens. The segment is projected to expand at a CAGR of 6.6% over the forecast period.
Browse Research Report On Research Antibodies Market :
On the basis of technology, the market is split into immunofluorescence, immunohistochemistry, flow cytometry, western blotting, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), and others. In 2016, western blotting dominated the global market in terms of revenue due to affordability and benefits like greater immunogenic response from infectious agents. High incidence of HIV and diseases with limited treatment options is anticipated to boost growth.
As per source, the market is categorized into mouse, rabbit, goat, and others. In 2016, the mouse segment held the largest market share. Better specificity and easy availability are the major driving factors. Based on application, the market is fragmented into infectious diseases, oncology, immunology, stem cells, neurobiology, and others. In 2016, oncology held over 36.0% of the total market share in terms of revenue due to high prevalence.
On the basis of end-use, the market is classified into academic and research institutes, pharmaceutical and biotechnology companies, and Contract Research Organizations (CRO). The pharmaceutical and biotechnology companies segment is likely to capture more than 61.0% of the overall market share in terms of revenue by 2025. Increasing use of research antibodies in drug development and discovery. The CRO segment is expected to be the fastest growing segment due to cost-effectiveness.
Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2016, North America dominated the market owing to enormous economic growth and existence of numerous biotechnology and biopharmaceutical manufacturers as well as academic institutes. Additionally, stringent regulations regarding production of antibodies is leading to development of high quality products. This factor is anticipated to impel regional market growth in near future.
Asia Pacific is expected to display substantial CAGR over the forecast period owing to increasing innovation. In addition, development of healthcare infrastructure along with establishment of favorable regulatory policies and safety guidelines by public healthcare organizations is also projected to support regional market growth.
Prominent companies operating in the research antibodies market include Thermo Fisher Scientific, Inc.; PerkinElmer, Inc.; Cell Signalling Technology, Inc.; Thermo Fisher Scientific; and Bio – Rad Laboratories.
View more reports of this category by Grand View Research at
Grand View Research has segmented the global research antibodies market on the basis of product, type, technology, source, application, end-use, and region:
Research Antibodies Product Outlook (Revenue, USD Million, 2014 – 2025)
Research Antibodies Type Outlook (Revenue, USD Million, 2014 – 2025)
- Monoclonal Antibodies
- Polyclonal Antibodies
Research Antibodies Technology Outlook (Revenue, USD Million, 2014 – 2025)
- Western Blotting
- Flow Cytometry
Research Antibodies Source Outlook (Revenue, USD Million, 2014 – 2025)
Research Antibodies Application Outlook (Revenue, USD Million, 2014 – 2025)
- Infectious Diseases
- Stem Cells
Research Antibodies End-use Outlook (Revenue, USD Million, 2014 – 2025)
- Academic & Research Institutes
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
Research Antibodies Regional Outlook (Revenue, USD Million, 2014 – 2025)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Browse Press Release of this Report:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com